When to Perform Bladder Catheterization in Fast-track Hip and Knee Arthroplasty

NCT ID: NCT02126813

Last Updated: 2015-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 40 % of all patients undergoing fast-track total hip or knee arthroplasty needs intermittent bladder catheterization after surgery, as they are transient incapable of voluntary bladder emptying (postoperative urinary retention - POUR). The currently used interventional threshold for urinary bladder catheterization are a bladder volume of approximately 500 ml., but no evidence exists for this threshold. At the same time, the current knowledge suggest, that a bladder volume up to 1000 ml. for 2-4 hours are safe in humans, and as the use of urinary bladder catheterization are increasing the risk of complications, the investigators are hypothesizing that increasing the interventional threshold for urinary bladder catheterization after fast-track total hip or knee arthroplasty, will reduce the number of patients needing urinary bladder catheterization, without increasing the incidence of urological complications - including urinary tract infections.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Urinary Retention (POUR)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

500 ml.

A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.

Group Type ACTIVE_COMPARATOR

Current used interventional threshold for urinary bladder catheterization (500 ml)

Intervention Type PROCEDURE

Intermittent bladder catheter

Intervention Type DEVICE

800 ml

A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.

Group Type EXPERIMENTAL

increased interventional threshold for urinary bladder catheterization (800 ml)

Intervention Type PROCEDURE

Intermittent bladder catheter

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

increased interventional threshold for urinary bladder catheterization (800 ml)

Intervention Type PROCEDURE

Current used interventional threshold for urinary bladder catheterization (500 ml)

Intervention Type PROCEDURE

Intermittent bladder catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* planned for elective total hip or knee arthroplasty
* given written informed consent for participation

Exclusion Criteria

* can't co-operate to participation
* can't speak or understand danish
* preoperative use of urinary bladder catheterization
* using haemodialysis
* previous cystectomy
* need for permanent urinary bladder catheter during surgery (decided by anaesthesiologist and/or surgeon)
* Pregnant or given birth within the last 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

125 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lundbeck Foundation

OTHER

Sponsor Role collaborator

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lars Bjerregaard

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lars Bjerregaard, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Copenhagen university, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalborg University Hospital, Farsoe

Farsø, , Denmark

Site Status

Department of Orthopaedics, Gentofte University Hospital

Hellerup, , Denmark

Site Status

Department of Orthopaedics, Vejle Hospital

Vejle, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

POUR-RCT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Urinary Retention After Arthroplasty
NCT04707001 RECRUITING NA
Anterior Advantage With KINCISE
NCT04191733 TERMINATED NA
The Q-REDUCE Study
NCT06639334 NOT_YET_RECRUITING NA